Login / Signup

Baricitinib for relapsing giant cell arteritis: a prospective open-label 52-week pilot study.

Matthew J KosterCynthia S CrowsonRachel E GiblonJane M JaquithAli Duarte GarciaEric L MattesonCornelia M WeyandKenneth J Warrington
Published in: Annals of the rheumatic diseases (2022)
NCT03026504.
Keyphrases
  • giant cell
  • open label
  • multiple sclerosis
  • clinical trial
  • phase ii
  • phase iii
  • phase ii study
  • study protocol
  • disease activity
  • randomized controlled trial
  • rheumatoid arthritis